系统性红斑狼疮患者接种SARS-CoV-2疫苗后的免疫应答与疾病状态评估
SLE患者抗SARS-CoV-2刺突RBD的IgG应答显著低于对照,28.8%患者IgG低于最低对照值;使用免疫抑制剂或泼尼松及接种前抗dsDNA抗体正常与应答降低相关。接种后严重疾病 flare 罕见(1.3%)。
要点
- SLE患者全程接种后IgG应答显著低于健康对照。
- 使用免疫抑制剂或泼尼松者疫苗应答降低。
- 接种后严重疾病 flare 罕见,为1.3%。
核心结论
- SLE患者全程接种新冠疫苗后约29%出现低应答,与接受免疫抑制治疗相关;严重疾病 flare 罕见。
主要发现
- SLE患者抗SARS-CoV-2刺突RBD的IgG抗体显著低于对照。
- 使用任何免疫抑制剂或泼尼松及接种前抗dsDNA抗体正常与疫苗应答降低相关。
- 抗RBD IgG与SARS-CoV-2微量中和滴度强相关,并与ELISpot检测的抗原特异性IFNγ产生相关。
- 部分抗体应答差的患者IFNγ产生同样减弱;接种前后SLEDAI评分相似,接种后 flare 发生率为11.4%,其中1.3%为严重。
关键数值与推荐
- IgG低应答定义为低于最低对照值(<100 units/ml),见于28.8%的SLE患者。
- 接种后 flare 发生率11.4%,严重 flare 占1.3%。
临床怎么用
- 对使用免疫抑制剂或泼尼松的SLE患者应关注疫苗应答降低可能,并考虑加强接种评估。
局限性
- 未报告保护性抗体阈值,需进一步研究加强接种方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate seroreactivity and disease flares after COVID-19 vaccination in a multiethnic/multiracial cohort of patients with systemic lupus erythematosus (SLE). METHODS: Ninety SLE patients and 20 healthy controls receiving a complete COVID-19 vaccine regimen were included. IgG seroreactivity to the SARS-CoV-2 spike receptor-binding domain (RBD) and SARS-CoV-2 microneutralization were used to evaluate B cell responses; interferon-γ (IFNγ) production was measured by enzyme-linked immunospot (ELISpot) assay in order to assess T cell responses. Disease activity was measured by the hybrid SLE Disease Activity Index (SLEDAI), and flares were identified according to the Safety of Estrogens in Lupus Erythematosus National Assessment-SLEDAI flare index. RESULTS: Overall, fully vaccinated SLE patients produced significantly lower IgG antibodies against SARS-CoV-2 spike RBD compared to fully vaccinated controls. Twenty-six SLE patients (28.8%) generated an IgG response below that of the lowest control (<100 units/ml). In logistic regression analyses, the use of any immunosuppressant or prednisone and a normal anti-double-stranded DNA antibody level prior to vaccination were associated with decreased vaccine responses. IgG seroreactivity to the SARS-CoV-2 spike RBD strongly correlated with the SARS-CoV-2 microneutralization titers and correlated with antigen-specific IFNγ production determined by ELISpot. In a subset of patients with poor antibody responses, IFNγ production was similarly diminished. Pre- and postvaccination SLEDAI scores were similar in both groups. Postvaccination flares occurred in 11.4% of patients; 1.3% of these were severe. CONCLUSION: In a multiethnic/multiracial study of SLE patients, 29% had a low response to the COVID-19 vaccine which was associated with receiving immunosuppressive therapy. Reassuringly, severe disease flares were rare. While minimal protective levels remain unknown, these data suggest that protocol development is needed to assess the efficacy of booster vaccination.
引用
- Izmirly PM, Kim MY, Samanovic M, et al. Evaluation of Immune Response and Disease Status in Systemic Lupus Erythematosus Patients Following SARS-CoV-2 Vaccination. Arthritis Rheumatol. 2021. PMID: 34347939. doi:10.1002/art.41937
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。